232 related articles for article (PubMed ID: 11370630)
1. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O; Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frébourg T
J Med Genet; 2001 Apr; 38(4):253-7. PubMed ID: 11370630
[No Abstract] [Full Text] [Related]
2. TP53, hChk2, and the Li-Fraumeni syndrome.
Varley J
Methods Mol Biol; 2003; 222():117-29. PubMed ID: 12710683
[TBL] [Abstract][Full Text] [Related]
3. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
Bell DW; Varley JM; Szydlo TE; Kang DH; Wahrer DC; Shannon KE; Lubratovich M; Verselis SJ; Isselbacher KJ; Fraumeni JF; Birch JM; Li FP; Garber JE; Haber DA
Science; 1999 Dec; 286(5449):2528-31. PubMed ID: 10617473
[TBL] [Abstract][Full Text] [Related]
4. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
5. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.
Upton B; Chu Q; Li BD
Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046
[TBL] [Abstract][Full Text] [Related]
6. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.
MacGeoch C; Turner G; Bobrow LG; Barnes DM; Bishop DT; Spurr NK
J Med Genet; 1995 Mar; 32(3):186-90. PubMed ID: 7783166
[TBL] [Abstract][Full Text] [Related]
8. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
9. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome.
Sodha N; Houlston RS; Bullock S; Yuille MA; Chu C; Turner G; Eeles RA
Hum Mutat; 2002 Dec; 20(6):460-2. PubMed ID: 12442270
[No Abstract] [Full Text] [Related]
10. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
11. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel TP53 germline mutation in a large Italian Li-Fraumeni syndrome Family.
Capra V; Consales A; Nozza P; Monti P; Inga A; Fronza G
Pediatr Blood Cancer; 2009 Feb; 52(2):303-4. PubMed ID: 18937320
[No Abstract] [Full Text] [Related]
13. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
[TBL] [Abstract][Full Text] [Related]
14. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
16. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H
Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205
[TBL] [Abstract][Full Text] [Related]
17. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
[TBL] [Abstract][Full Text] [Related]
18. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
[TBL] [Abstract][Full Text] [Related]
20. Screening hCHK2 for mutations.
Sodha N; Williams R; Mangion J; Bullock SL; Yuille MR; Eeles RA
Science; 2000 Jul; 289(5478):359. PubMed ID: 10939935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
